Is Lipid Accumulation Product Associated with an Atherogenic Lipoprotein Profile in Brazilian Subjects?
| Autor: | Nágila Raquel Teixeira Damasceno, Caroline Pappiani, Flávia de Conti Cartolano, Maria Camila Prupper de Freitas, Antônio Augusto Ferreira Carioca, Antônio Martins Figueiredo Neto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Fatores de Risco
Blood Glucose Male Dislipidemias lcsh:Diseases of the circulatory (Cardiovascular) system Apolipoprotein B Doenças Cardiovasculares medicine.medical_treatment Fibrate Fatty Acids Nonesterified 030204 cardiovascular system & hematology chemistry.chemical_compound 0302 clinical medicine Reference Values Risk Factors Insulin Anthropometry biology Lipoproteínas LDL Middle Aged Lipoproteins LDL Cardiovascular Diseases Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine Lipoproteins HDL Brazil Adult medicine.medical_specialty medicine.drug_class Resistência à Insulina 030209 endocrinology & metabolism Risk Assessment 03 medical and health sciences Sex Factors NEFA Insulin resistance Internal medicine medicine Humans Adults Adultos Lipoproteínas HDL Aged Apolipoproteins B Dyslipidemias Apolipoprotein A-I Cholesterol business.industry Cholesterol HDL Cholesterol LDL Original Articles Atherosclerosis medicine.disease Endocrinology chemistry lcsh:RC666-701 biology.protein Insulin Resistance Epidemiologic Methods Lipid Accumulation Product business Biomarkers Lipoprotein |
| Zdroj: | Arquivos Brasileiros de Cardiologia v.110 n.4 2018 Arquivos Brasileiros de Cardiologia Sociedade Brasileira de Cardiologia (SBC) instacron:SBC Arquivos Brasileiros de Cardiologia, Vol 110, Iss 4, Pp 339-347 |
| Popis: | Background: Lipid accumulation product (LAP), a simple and low-cost tool, is a novel biomarker of central lipid accumulation and represents a potential surrogate marker for atherogenic lipoprotein profile. However, its association with lipoprotein subfractions has not been described in the literature. Objective: To determine whether LAP index could be used as a marker of low- and high-density lipoprotein (LDL and HDL) size in Brazilian individuals. Methods: This cross-sectional study included patients (n = 351) of both sexes and age between 30-74 years. Clinical and sociodemographic data and family history of diseases were evaluated. Lipoprotein size, and levels of total cholesterol (TC), lipoproteins, apolipoprotein AI and B (APO AI/APO B), glucose, insulin, insulin resistance index (HOMA-IR) and non-esterified fatty acids (NEFA) were assessed in blood samples. LAP was calculated by the formulas [(waist circumference[cm]-58) × (triglycerides[mmol/L]) for women and (waist circumference [cm]-65) × (triglycerides [mmol/L]) for men]. The association between LAP and metabolic parameters were tested by linear trend (general linear model, GLM test) before and after multiple adjustments for potential confounders (sex, age, smoking, statin, fibrate, and hypoglycemic drugs) at significant level p < 0.05. Results: LAP was positively associated with TC, APO B, NEFA, glucose, insulin and HOMA-IR values, and negatively associated with HDL-C. Higher central lipid accumulation was corelated with higher percentage of intermediate HDL and of small LDL and HDL and less amount of large HDL. LDL size was also reduced in greater LAP index values. The negative impact of LAP was maintained after adjustment for multiple variables. Conclusion: LAP was robustly associated with atherogenic profile of lipoprotein subfractions, independently of multiple confounders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|